vTv Therapeutics regains compliance with Nasdaq after 1-for-40 reverse stock split

High Point's biopharmaceutical company vTv Therapeutics is back in good standing with Nasdaq after months of being in danger of being delisted. At its lowest point in the past year, the company's stock had traded for $0.35 per share. Find out just how big a jump the stock price took and if this means the company, which is developing an oral treatment for Type 1 diabetes, is truly in good financial standing.

Previous Advocate Health appoints industry veteran Brad Clark as new CFO
Next Blue Cross and Blue Shield of New Mexico to open neighborhood center in Las Estancias